Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Multicentre, Randomized, Double-blind and Placebo Controlled Phase-III Study With Rituximab Induction and Maintenance Treatment.

NCT02229942 is registered in ClinicalTrials.gov with Haukeland University Hospital as lead sponsor.

NCT NCT02229942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02229942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Multicentre, Randomized, Double-blind and Placebo Controlled Phase-III Study With Rituximab Induction and Maintenance Treatment.
Lead sponsor
Haukeland University Hospital
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2014
Completion date
November 30, 2017
Enrollment
151 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chronic fatigue syndrome/ myalgic encephalitis (cfs/me)